The study showed 100% healing when Myriad™ was used in six surgical reconstructions of soft tissue defects with exposed vital structures and included a variety of different wound types; e.g. full thickness scalp excision, scar revision surgery, tumor (squamous cell carcinoma) excision, traumatic wound, surgical dehiscence, and fistula.
“Some of the procedures where Myriad™ performed well are very high-volume procedures. For example, the American Society of Plastic Surgeonsi estimates there are 4.4 million tumor resections per annum and around 180,000 scar revision procedures each year in the US, so it is very positive to see this proven efficacy and absence of complications,”
- Forums
- ASX - By Stock
- ARX
- Ann: New Study Shows Myriad Efficacy in Exposed Vital Structures
Ann: New Study Shows Myriad Efficacy in Exposed Vital Structures, page-2
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ARX (ASX) to my watchlist
(20min delay)
|
|||||
Last
54.5¢ |
Change
-0.005(0.91%) |
Mkt cap ! $187.9M |
Open | High | Low | Value | Volume |
53.5¢ | 54.5¢ | 53.0¢ | $121.0K | 224.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6162 | 53.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
54.5¢ | 2266 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6162 | 0.530 |
3 | 59923 | 0.520 |
1 | 11000 | 0.515 |
2 | 5944 | 0.510 |
2 | 9980 | 0.505 |
Price($) | Vol. | No. |
---|---|---|
0.545 | 2266 | 2 |
0.550 | 92429 | 2 |
0.555 | 747 | 1 |
0.560 | 19989 | 1 |
0.565 | 1769 | 1 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
ARX (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online